Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly turns to Amylin

Executive Summary

Lilly will collaborate with Amylin on the development of AC2993 for type 2 diabetes, following Lilly's decision not to pursue Phase III studies of its in-house glucagon-like peptide-1 analogue. Lilly opted not to proceed to Phase III with its drug because of a technical failure in the formulation that caused adverse effects at the injection site, company says. AC2993 has a similar mechanism of action and is in Phase III; the companies hope to file an NDA in 2004. Agreement calls for Lilly to make an $80 mil. upfront payment and purchase $30 mil. in equity. Amylin will receive up to $215 mil. in additional milestone payments, and companies will split U.S. profits equally. Amylin previously worked with Johnson & Johnson on the development of Symlin (pramlintide), but J&J withdrew from the agreement...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

PS040510

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel